Home
INMB
INMB News

Latest INmune Bio Inc. Common stock (INMB) News on January 22, 2025

Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks

TipRanks

10 days ago

Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

GlobeNewswire

a month ago

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

OmniScience and INmune Bio Partner for Alzheimer’s Trial

Exec Edge

2 months ago

OmniScience and INmune Bio Partner for Alzheimer’s Trial

MT Newswires

2 months ago

INmune Bio Partners With OmniScience to Accelerate Alzheimer's Trial

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Business Wire

2 months ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

GlobeNewswire

2 months ago

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)

Simply Wall St.

3 months ago

INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)

INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

GuruFocus.com

3 months ago

INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

GlobeNewswire

3 months ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For

GuruFocus.com

3 months ago

INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

GlobeNewswire

3 months ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares

GuruFocus.com

3 months ago

Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

GlobeNewswire

3 months ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

GlobeNewswire

3 months ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Insider Stock Buying Reaches US$951.2k On INmune Bio

Simply Wall St.

3 months ago

Insider Stock Buying Reaches US$951.2k On INmune Bio

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

GlobeNewswire

3 months ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs

GuruFocus.com

3 months ago

INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 10/01/2024

MT Newswires

4 months ago

INmune Bio Closes Enrollment for Phase 2 XPro Trial in Early Alzheimer's Disease

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

GlobeNewswire

4 months ago

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

GlobeNewswire

4 months ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

MT Newswires

4 months ago

INmune Bio Says AD02 Trial for Alzheimer's Disease Reveals Strong Performance of EMACC Cognitive Measure

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

GlobeNewswire

4 months ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

MT Newswires

4 months ago

INmune Bio Launches $13 Million Registered Direct Offering of Common Shares, Warrants

INmune Bio Announces $13.0 Million Registered Direct Offering

GlobeNewswire

4 months ago

INmune Bio Announces $13.0 Million Registered Direct Offering

INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions

Simply Wall St.

4 months ago

INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

GlobeNewswire

5 months ago

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

INmune Bio Second Quarter 2024 Earnings: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023)

Simply Wall St.

6 months ago

INmune Bio Second Quarter 2024 Earnings: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023)

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

GlobeNewswire

6 months ago

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

GlobeNewswire

6 months ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

GlobeNewswire

6 months ago

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

GlobeNewswire

6 months ago

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment

Simply Wall St.

6 months ago

Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment

INmune Bio’s unique Alzheimer’s trial endpoint receives validation

Clinical Trials Arena

7 months ago

INmune Bio’s unique Alzheimer’s trial endpoint receives validation

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

GlobeNewswire

7 months ago

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

MT Newswires

8 months ago

Sector Update: Health Care Stocks Higher in Afternoon Trading

MT Newswires

8 months ago

INmune Bio to Join Russell 3000 Index in July

INmune Bio Inc. to Join Russell 3000® Index

GlobeNewswire

8 months ago

INmune Bio Inc. to Join Russell 3000® Index

INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript

Insider Monkey

8 months ago

INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript

INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations

Simply Wall St.

8 months ago

INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

GlobeNewswire

8 months ago

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

GlobeNewswire

8 months ago

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

GlobeNewswire

9 months ago

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire

9 months ago

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

INmune Bio Independent Director Acquires 80% More Stock

Simply Wall St.

9 months ago

INmune Bio Independent Director Acquires 80% More Stock

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

9 months ago

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

GlobeNewswire

9 months ago

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

GlobeNewswire

9 months ago

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

GlobeNewswire

9 months ago

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

10 months ago

INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements

GuruFocus.com

10 months ago

INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

GlobeNewswire

10 months ago

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

GlobeNewswire

10 months ago

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

GlobeNewswire

10 months ago

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

GlobeNewswire

a year ago

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire

a year ago

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

GlobeNewswire

a year ago

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

Insiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the company

Simply Wall St.

a year ago

Insiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the company

Clearfield (CLFD) Reports Q1 Loss, Tops Revenue Estimates

Zacks

a year ago

Clearfield (CLFD) Reports Q1 Loss, Tops Revenue Estimates

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

GlobeNewswire

a year ago

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

12 Highest Rated Mattresses Under $1000

Insider Monkey

a year ago

12 Highest Rated Mattresses Under $1000

Third Coast Bancshares, Inc. (TCBX) Q4 Earnings and Revenues Top Estimates

Zacks

a year ago

Third Coast Bancshares, Inc. (TCBX) Q4 Earnings and Revenues Top Estimates

ATSG Announces New President of Airline Subsidiary ATI

Business Wire

a year ago

ATSG Announces New President of Airline Subsidiary ATI

Capital Bancorp Inc (CBNK) Reports Steady Earnings Amid Market Volatility

GuruFocus.com

a year ago

Capital Bancorp Inc (CBNK) Reports Steady Earnings Amid Market Volatility

Associated Press Finance

a year ago

Capital Bancorp: Q4 Earnings Snapshot

Virtus Diversified Income & Convertible Fund Discloses Sources of Distribution – Section 19(a) Notice

Business Wire

a year ago

Virtus Diversified Income & Convertible Fund Discloses Sources of Distribution – Section 19(a) Notice

WhiteHorse Finance, Inc. To Report Fourth Quarter 2023 and Full Year Financial Results

PR Newswire

a year ago

WhiteHorse Finance, Inc. To Report Fourth Quarter 2023 and Full Year Financial Results

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa

Business Wire

a year ago

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa

GDEV announces final results of previously announced self tender offer to purchase for cash a minimum of 15,000,000, up to 20,000,000 of its ordinary shares at a purchase price of $2.00 per ordinary share

GlobeNewswire

a year ago

GDEV announces final results of previously announced self tender offer to purchase for cash a minimum of 15,000,000, up to 20,000,000 of its ordinary shares at a purchase price of $2.00 per ordinary share

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

GlobeNewswire

a year ago

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

Business Wire

a year ago

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...

GuruFocus.com

a year ago

Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...

Business Wire

a year ago

First Trust Energy Income and Growth Fund Declares its Quarterly Distribution of $0.30 Per Share

MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions

Zacks

a year ago

MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions

Euroseas Ltd. (ESEA) Soars 6.3%: Is Further Upside Left in the Stock?

Zacks

a year ago

Euroseas Ltd. (ESEA) Soars 6.3%: Is Further Upside Left in the Stock?

Getty Realty Corp. Provides 2023 Business Update

Business Wire

a year ago

Getty Realty Corp. Provides 2023 Business Update

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

Zacks

a year ago

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

Reuters

a year ago

UPDATE 2-Allogene to cut 22% of its workforce

Reuters

a year ago

Allogene to cut 22% of its workforce

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

GlobeNewswire

a year ago

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire

a year ago

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

AI, taxes, real estate, healthcare: Best of 2023 theme weeks

Yahoo Finance Video

a year ago

AI, taxes, real estate, healthcare: Best of 2023 theme weeks

Unisys Wins Coveted "The Drum Award" in the B2B Rebrand or Relaunch Category

PR Newswire

a year ago

Unisys Wins Coveted "The Drum Award" in the B2B Rebrand or Relaunch Category

XOMA Declares Quarterly Preferred Stock Dividends

GlobeNewswire

a year ago

XOMA Declares Quarterly Preferred Stock Dividends

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

GlobeNewswire

a year ago

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

Peapack-Gladstone Bank’s Boonton Charity Christmas Tree Sale Supports Sound Start Foundation

GlobeNewswire

a year ago

Peapack-Gladstone Bank’s Boonton Charity Christmas Tree Sale Supports Sound Start Foundation

Unisys Revises Estimate of One-Time, Non-Cash, Pre-Tax Settlement Charge Related to Previously Announced Purchase of Group Annuity Contracts

PR Newswire

a year ago

Unisys Revises Estimate of One-Time, Non-Cash, Pre-Tax Settlement Charge Related to Previously Announced Purchase of Group Annuity Contracts

SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference

GlobeNewswire

a year ago

SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference

SoundThinking Expands into Latin America with Launch of ShotSpotter in Montevideo, Uruguay

GlobeNewswire

a year ago

SoundThinking Expands into Latin America with Launch of ShotSpotter in Montevideo, Uruguay

Option Care Health to Participate in the J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Option Care Health to Participate in the J.P. Morgan Healthcare Conference

NeoGames’ Pariplay signs deal with Tipico US for further North American growth

GlobeNewswire

a year ago

NeoGames’ Pariplay signs deal with Tipico US for further North American growth

Calculating The Fair Value Of FutureFuel Corp. (NYSE:FF)

Simply Wall St.

a year ago

Calculating The Fair Value Of FutureFuel Corp. (NYSE:FF)

Thomson Reuters StreetEvents

a year ago

Q4 2023 Liquidity Services Inc Earnings Call

Liquidity Services Inc (LQDT) Reports Growth in GMV and Revenue for Q4 Fiscal Year 2023

GuruFocus.com

a year ago

Liquidity Services Inc (LQDT) Reports Growth in GMV and Revenue for Q4 Fiscal Year 2023

SoundThinking Sets Upcoming Financial Conference Schedule

GlobeNewswire

a year ago

SoundThinking Sets Upcoming Financial Conference Schedule

Insider Sell Alert: CFO Sonia Jain Sells 39,191 Shares of Cars.com Inc

GuruFocus.com

a year ago

Insider Sell Alert: CFO Sonia Jain Sells 39,191 Shares of Cars.com Inc

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

GlobeNewswire

a year ago

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

GlobeNewswire

a year ago

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

McEwen Mining Announces Flow-Through Financing

GlobeNewswire

a year ago

McEwen Mining Announces Flow-Through Financing

Share on Social Networks: